Pliant Therapeutics (PLRX) Stock Forecast, Price Target & Predictions
PLRX Stock Forecast
Pliant Therapeutics stock forecast is as follows: an average price target of $39.71 (represents a 211.94% upside from PLRX’s last price of $12.73) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
PLRX Price Target
The average price target for Pliant Therapeutics (PLRX) is $39.71 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $48.00 to $32.00. This represents a potential 211.94% upside from PLRX's last price of $12.73.
PLRX Analyst Ratings
According to 5 Wall Street analysts, Pliant Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for PLRX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Pliant Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | Ed Arce | H.C. Wainwright | $38.00 | $11.84 | 220.95% | 198.51% |
| Sep 09, 2024 | Faisal Khurshid | Leerink Partners | $33.00 | $12.87 | 156.41% | 159.23% |
| May 23, 2024 | Yasmeen Rahimi | Piper Sandler | $40.00 | $13.85 | 188.81% | 214.22% |
| May 07, 2024 | Alex Thompson | Stifel Nicolaus | $32.00 | $13.91 | 130.05% | 151.37% |
| May 07, 2024 | Jeff Jones | Oppenheimer | $48.00 | $13.79 | 248.08% | 277.06% |
| May 07, 2024 | Ed Arce | H.C. Wainwright | $36.00 | $13.79 | 161.06% | 182.80% |
| May 07, 2024 | Brian Abrahams | RBC Capital | $45.00 | $13.79 | 226.32% | 253.50% |
| Dec 07, 2022 | - | J.P. Morgan | $42.00 | $17.18 | 144.47% | 229.93% |
The latest Pliant Therapeutics stock forecast, released on Sep 13, 2024 by Ed Arce from H.C. Wainwright, set a price target of $38.00, which represents a 220.95% increase from the stock price at the time of the forecast ($11.84), and a 198.51% increase from PLRX last price ($12.73).
Pliant Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 7 |
| Avg Price Target | - | $35.50 | $38.86 |
| Last Closing Price | $12.73 | $12.73 | $12.73 |
| Upside/Downside | -100.00% | 178.87% | 205.26% |
In the current month, the average price target of Pliant Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Pliant Therapeutics's last price of $12.73. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 06, 2024 | Citigroup | Buy | Buy | Hold |
| May 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 07, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 07, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 07, 2024 | Citigroup | Buy | Buy | Hold |
| Mar 01, 2022 | RBC Capital | Outperform | Outperform | Hold |
Pliant Therapeutics's last stock rating was published by Piper Sandler on Sep 17, 2024. The company gave PLRX a "Overweight" rating, the same as its previous rate.
Pliant Therapeutics Financial Forecast
Pliant Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $4.84M | - | $248.00K | $1.33M | $1.97M | $1.48M | $4.99M | $1.25M | $2.00M | $1.61M | $1.79M | $2.17M | $4.46M | $4.81M | $3.60M |
| Avg Forecast | - | - | - | - | $250.00K | $250.00K | $250.00K | $250.00K | $125.00K | $472.22K | $732.50K | $580.63K | $814.11K | $1.02M | $1.21M | $1.39M | $1.45M | $1.79M | $1.35M | $1.26M | $3.00M | $3.17M | $4.17M | $4.23M | $3.37M | $2.50M | $3.70M |
| High Forecast | - | - | - | - | $250.00K | $250.00K | $250.00K | $250.00K | $125.00K | $472.33K | $732.75K | $580.81K | $814.11K | $1.02M | $1.21M | $1.39M | $1.45M | $1.79M | $1.35M | $1.26M | $3.00M | $3.17M | $4.17M | $4.23M | $3.37M | $2.50M | $3.70M |
| Low Forecast | - | - | - | - | $250.00K | $250.00K | $250.00K | $250.00K | $125.00K | $472.11K | $732.25K | $580.44K | $814.11K | $1.02M | $1.21M | $1.39M | $1.45M | $1.79M | $1.35M | $1.26M | $3.00M | $3.17M | $4.17M | $4.23M | $3.37M | $2.50M | $3.70M |
| # Analysts | - | - | - | - | 3 | 3 | 3 | 5 | 12 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 5.95% | - | 0.20% | 0.96% | 1.35% | 0.83% | 3.70% | 0.99% | 0.67% | 0.51% | 0.43% | 0.51% | 1.33% | 1.93% | 0.97% |
Pliant Therapeutics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $580.63K, with a low forecast of $580.44K, and a high forecast of $580.81K. PLRX's average Quarter revenue forecast represents a -88.00% decrease compared to the company's last Quarter revenue of $4.84M (Dec 23).
Pliant Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 3 | 3 | 3 | 5 | 12 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-46.57M | $-47.69M | $-47.33M | $-36.78M | $-34.74M | $-31.49M | $-29.18M | $-27.76M | $-23.84M | $-26.66M | $-22.46M | $-22.50M | $-18.68M | $-16.20M | $-16.68M |
| Avg Forecast | - | - | - | - | $-198.33K | $-198.33K | $-198.33K | $-198.33K | $-99.17K | $-374.63K | $-581.11K | $-42.30M | $-645.86K | $-811.91K | $-961.91K | $-33.44M | $-24.64M | $-1.43M | $-1.08M | $-26.43M | $-2.40M | $-2.53M | $-3.33M | $-21.00M | $-2.69M | $-2.00M | $-10.30M |
| High Forecast | - | - | - | - | $-198.33K | $-198.33K | $-198.33K | $-198.33K | $-99.17K | $-374.54K | $-580.91K | $-33.84M | $-645.86K | $-811.91K | $-961.91K | $-26.75M | $-19.71M | $-1.43M | $-1.08M | $-21.15M | $-2.40M | $-2.53M | $-3.33M | $-16.80M | $-2.69M | $-2.00M | $-8.24M |
| Low Forecast | - | - | - | - | $-198.33K | $-198.33K | $-198.33K | $-198.33K | $-99.17K | $-374.71K | $-581.31K | $-50.76M | $-645.86K | $-811.91K | $-961.91K | $-40.12M | $-29.57M | $-1.43M | $-1.08M | $-31.72M | $-2.40M | $-2.53M | $-3.33M | $-25.20M | $-2.69M | $-2.00M | $-12.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 72.11% | 58.73% | 49.20% | 1.10% | 1.41% | 21.97% | 27.04% | 1.05% | 9.94% | 10.53% | 6.74% | 1.07% | 6.94% | 8.11% | 1.62% |
undefined analysts predict PLRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Pliant Therapeutics's previous annual EBITDA (undefined) of $NaN.
Pliant Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 3 | 3 | 3 | 5 | 12 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-41.11M | $-41.49M | $-41.19M | $-28.14M | $-34.60M | $-27.95M | $-29.35M | $-27.88M | $-24.80M | $-27.05M | $-22.83M | $-22.86M | $-19.03M | $-16.53M | $-17.00M |
| Avg Forecast | $-60.12M | $-61.95M | $-61.95M | $-61.95M | $-65.68M | $-63.68M | $-61.95M | $-60.38M | $-60.02M | $-58.86M | $-51.53M | $-43.17M | $-49.41M | $-47.08M | $-43.32M | $-34.12M | $-25.35M | $-44.75M | $-49.05M | $-26.98M | $-45.93M | $-41.69M | $-40.47M | $-21.33M | $-43.02M | $-51.24M | $-10.49M |
| High Forecast | $-60.12M | $-61.95M | $-61.95M | $-61.95M | $-65.68M | $-63.68M | $-61.95M | $-54.09M | $-49.28M | $-58.86M | $-51.53M | $-34.53M | $-45.45M | $-47.08M | $-43.32M | $-27.30M | $-20.28M | $-44.75M | $-49.05M | $-21.58M | $-45.93M | $-41.69M | $-40.47M | $-17.07M | $-43.02M | $-51.24M | $-8.40M |
| Low Forecast | $-60.12M | $-61.95M | $-61.95M | $-61.95M | $-65.68M | $-63.68M | $-61.95M | $-63.53M | $-64.44M | $-58.86M | $-51.53M | $-51.80M | $-61.26M | $-47.08M | $-43.32M | $-40.95M | $-30.42M | $-44.75M | $-49.05M | $-32.37M | $-45.93M | $-41.69M | $-40.47M | $-25.60M | $-43.02M | $-51.24M | $-12.59M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.83% | 0.88% | 0.95% | 0.82% | 1.37% | 0.62% | 0.60% | 1.03% | 0.54% | 0.65% | 0.56% | 1.07% | 0.44% | 0.32% | 1.62% |
Pliant Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PLRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Pliant Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 3 | 3 | 3 | 5 | 12 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $13.85M | $15.35M | $14.57M | $14.15M | $14.25M | $8.82M | $8.30M | $8.58M | $-47.27M | $7.67M | $5.47M | $6.57M | $5.63M | $4.59M | $3.04M |
| Avg Forecast | - | - | - | - | $2.25M | $2.25M | $2.25M | $2.25M | $1.13M | $4.25M | $6.60M | $5.23M | $7.33M | $9.22M | $10.92M | $12.50M | $-48.85M | $16.14M | $12.16M | $11.35M | $27.02M | $28.52M | $37.53M | $38.13M | $30.32M | $22.52M | $1.88M |
| High Forecast | - | - | - | - | $2.25M | $2.25M | $2.25M | $2.25M | $1.13M | $4.25M | $6.60M | $5.23M | $7.33M | $9.22M | $10.92M | $12.50M | $-39.08M | $16.14M | $12.16M | $11.35M | $27.02M | $28.52M | $37.53M | $38.13M | $30.32M | $22.52M | $2.25M |
| Low Forecast | - | - | - | - | $2.25M | $2.25M | $2.25M | $2.25M | $1.13M | $4.25M | $6.59M | $5.23M | $7.33M | $9.22M | $10.92M | $12.50M | $-58.62M | $16.14M | $12.16M | $11.35M | $27.02M | $28.52M | $37.53M | $38.13M | $30.32M | $22.52M | $1.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.89% | 1.66% | 1.33% | 1.13% | -0.29% | 0.55% | 0.68% | 0.76% | -1.75% | 0.27% | 0.15% | 0.17% | 0.19% | 0.20% | 1.62% |
Pliant Therapeutics's average Quarter SG&A projection for Mar 24 is $5.23M, based on 3 Wall Street analysts, with a range of $5.23M to $5.23M. The forecast indicates a -62.25% fall compared to PLRX last annual SG&A of $13.85M (Dec 23).
Pliant Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 3 | 3 | 3 | 5 | 12 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.69 | $-0.70 | $-0.00 | $-0.50 | $-0.71 | $-0.60 | $-0.81 | $-0.77 | $-0.69 | $-0.75 | $-0.64 | $-0.64 | $-0.54 | $-0.47 | $-1.39 |
| Avg Forecast | $-0.99 | $-1.02 | $-1.02 | $-1.02 | $-1.08 | $-1.05 | $-1.02 | $-0.99 | $-0.99 | $-0.97 | $-0.85 | $-0.77 | $-0.81 | $-0.78 | $-0.71 | $-0.67 | $-0.70 | $-0.74 | $-0.81 | $-0.75 | $-0.76 | $-0.69 | $-0.67 | $-0.60 | $-0.71 | $-0.85 | $-0.86 |
| High Forecast | $-0.99 | $-1.02 | $-1.02 | $-1.02 | $-1.08 | $-1.05 | $-1.02 | $-0.89 | $-0.81 | $-0.97 | $-0.85 | $-0.77 | $-0.75 | $-0.78 | $-0.71 | $-0.67 | $-0.70 | $-0.74 | $-0.81 | $-0.75 | $-0.76 | $-0.69 | $-0.67 | $-0.60 | $-0.71 | $-0.85 | $-0.86 |
| Low Forecast | $-0.99 | $-1.02 | $-1.02 | $-1.02 | $-1.08 | $-1.05 | $-1.02 | $-1.05 | $-1.06 | $-0.97 | $-0.85 | $-0.77 | $-1.01 | $-0.78 | $-0.71 | $-0.67 | $-0.70 | $-0.74 | $-0.81 | $-0.75 | $-0.76 | $-0.69 | $-0.67 | $-0.60 | $-0.71 | $-0.85 | $-0.86 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.85% | 0.90% | 0.00% | 0.75% | 1.01% | 0.81% | 1.00% | 1.03% | 0.91% | 1.09% | 0.95% | 1.06% | 0.76% | 0.55% | 1.62% |
According to undefined Wall Street analysts, Pliant Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PLRX previous annual EPS of $NaN (undefined).
Pliant Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.51 | $6.00 | 1076.47% | Buy |
| BDTX | Black Diamond Therapeutics | $2.43 | $14.75 | 507.00% | Buy |
| INZY | Inozyme Pharma | $2.79 | $14.67 | 425.81% | Buy |
| RLAY | Relay Therapeutics | $4.66 | $19.40 | 316.31% | Buy |
| ARVN | Arvinas | $22.69 | $71.00 | 212.91% | Buy |
| PLRX | Pliant Therapeutics | $12.73 | $39.71 | 211.94% | Buy |
| ETNB | 89bio | $7.98 | $22.00 | 175.69% | Buy |
| STOK | Stoke Therapeutics | $11.31 | $30.60 | 170.56% | Buy |
| SNDX | Syndax Pharmaceuticals | $15.95 | $34.30 | 115.05% | Buy |
| VRDN | Viridian Therapeutics | $19.79 | $37.92 | 91.61% | Buy |
| CYTK | Cytokinetics | $49.86 | $83.23 | 66.93% | Buy |
| DYN | Dyne Therapeutics | $29.99 | $43.88 | 46.32% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $57.07 | $60.63 | 6.24% | Buy |
| MDGL | Madrigal Pharmaceuticals | $317.09 | $315.75 | -0.42% | Buy |
| ACLX | Arcellx | $87.22 | $83.00 | -4.84% | Buy |